Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
Indications↗
Distinct diseases across all programs
Clinical Trials↗
All sponsored trials (all statuses)
Pipeline
By Phase
12 drugs in development
By Therapeutic Area
top 3
R&D Momentum
81/100
Pipeline Velocity
58/100
Trial Completion Rate
61/100
Pipeline Concentration
52/100
Pipeline Freshness
68/100
Strategic Signals
Activity
Last 14 days
A Scalable Cruciferous Vegetable Intervention to Reduce Bladder Cancer Recurrence and Progression
A Phase 1, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of GB-5267, an IL-18 Armored CAR T Cell Product Targeting MUC16, in Patients With Platinum-Resistant Ovarian Cancer
Phase II Trial: Photoimmunotherapy and Anti-PD1 in Patients With Refractory Inoperable and Metastatic Non-Small Cell Lung Cancer
A Sustainable Nutrition Security Intervention for Low-Income Households
A Phase I Clinical Trial Investigating Autologous CAR T Cells Targeting GPC3 in Relapsed or Refractory Hepatocellular Carcinoma
Investigating the Feasibility of Using Transperineal Micro-Ultrasound to Detect Clinically Significant Prostate Cancer
A Pilot Study Using a Cranial Electrotherapy Stimulation (CES) Device in Conjunction With Life Coaching to Alleviate Burnout Symptoms in HealthCare Workers (HCWs)
A Phase II Study of CPX-351 in Younger Patients < 60 Years Old With Secondary Acute Myeloid Leukemia
Details
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
Pipeline
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)